As of May 27
| +0.33 / +4.67%|
The 1 analysts offering 12-month price forecasts for ZIOPHARM Oncology Inc have a median target of 21.00, with a high estimate of 21.00 and a low estimate of 21.00. The median estimate represents a +184.17% increase from the last price of 7.39.
The current consensus among 4 polled investment analysts is to Hold stock in ZIOPHARM Oncology Inc. This rating has held steady since May, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.